Research Progress of BRAF Fusion in Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 782-788, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-1010086
ABSTRACT
In advanced non-small cell lung cancer (NSCLC), V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation is highly malignant and has poor prognosis, and currently Dabrafenib in combination with Trametinib is approved for first-line treatment of patients with BRAF V600 mutation. In addition to mutations, BRAF fusion can also occur. With the development of gene detection, the detection of BRAF fusion is gradually increasing, but there is a lack of effective therapeutic strategies for BRAF fusion. In this paper, we review the clinical characteristics, mechanism of action, and clinical treatment of BRAF fusion to provide a basis for the treatment of BRAF fusion in NSCLC patients.
.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Proteínas Proto-Oncogénicas B-raf
/
Neoplasias Pulmonares
/
Mutación
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS